Form 4: Aprea CFO Hamill Boosts Stake with Equity Grants

Aprea Therapeutics' Senior VP and CFO, John P. Hamill, acquired 10,095 restricted stock units and 40,380 stock options, signaling continued alignment with shareholder interests.

Summary

• John P. Hamill, Senior VP, CFO, and Principal Financial & Accounting Officer of Aprea Therapeutics, Inc. (APRE), acquired equity awards on March 12, 2026.
• The awards include 10,095 restricted stock units (RSUs) and 40,380 stock options.
• The RSUs will vest in three equal annual installments beginning March 12, 2027, subject to continued employment.
• The stock options have an exercise price of $0.765 and will vest 25% on March 12, 2027, with the remainder vesting ratably over the subsequent 36 months, also subject to continued employment.
• Following these transactions, Mr. Hamill directly beneficially owns 43,528 shares of common stock and 40,380 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a key executive is increasing their stake in the company through equity grants, aligning their incentives with long-term shareholder value. It reflects confidence and commitment from management.

Positives

• Grant of 10,095 restricted stock units (RSUs) to a key executive, aligning management's interests with long-term shareholder value.
• Grant of 40,380 stock options with an exercise price of $0.765, providing a direct incentive for the executive to increase the company's share price.
• The equity awards demonstrate the company's commitment to retaining and incentivizing its Senior VP and CFO.

Risks

• The vesting of both restricted stock units and stock options is contingent upon John P. Hamill's continued employment through the specified vesting dates, posing a risk if his employment ceases.

Future Outlook

The equity grants, with their multi-year vesting schedules extending to March 2027 and beyond, indicate a long-term incentive structure designed to align the Senior VP and CFO's interests with the sustained growth and performance of Aprea Therapeutics.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the CFO are a standard practice in the biotechnology and pharmaceutical industries. This compensation structure is crucial for attracting and retaining top talent, especially in companies like Aprea Therapeutics, which often have long development cycles and rely on future milestones for value creation. Such grants incentivize executives to drive long-term strategic goals and enhance shareholder value, a common theme across peers in the sector.

Comparison to Industry Standards

• Equity compensation, including restricted stock units and stock options, is a prevalent method for executive incentives across the biotech industry.
• While specific grant sizes vary based on company stage, market capitalization, and executive role, the structure of multi-year vesting tied to continued employment is standard.
• For instance, similar practices are observed at companies like BioNTech SE (BNTX) for their executive team, where long-term incentives are critical given the R&D-intensive nature of the business.
• The exercise price of $0.765 for the options is specific to Aprea's current valuation, but the mechanism is comparable to grants at other development-stage biotechs aiming to tie executive wealth to stock performance.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of management's interests with long-term shareholder value.
• Employees: May signal stability and confidence in the company's future direction from top management.

Next Steps

• Vesting of 10,095 restricted stock units in three equal annual installments beginning March 12, 2027.
• Vesting of 25% of 40,380 stock options on March 12, 2027, with the remainder vesting ratably over the following 36 months.

Key Dates

Recommendation

The acquisition of equity by a key executive like the CFO is generally a positive signal, indicating management's belief in the company's future prospects and aligning their interests with shareholders. While not a standalone 'strong buy' signal, it reinforces a 'hold' position for existing investors and provides a positive data point for potential investors, suggesting internal confidence in long-term value creation.

Keywords

Aprea Therapeutics, APRE, Form 4, insider transaction, equity grant, restricted stock units, RSU, stock options, CFO, executive compensation, beneficial ownership